US employers consider reducing coverage for weight-loss drugs
美國雇主考慮減少對減肥藥物的承保範圍
更新於: 2026年8月31日 上午12:30
The landscape of U.S. healthcare benefits is currently defined by a tug-of-war over GLP-1 weight-loss drugs like Wegovy and Zepbound.
美國醫療福利的前景目前正處於針對 Wegovy 和 Zepbound 等 GLP-1 減重藥物的拉鋸戰中。
With monthly costs often exceeding $1,000 per patient, many employers are re-evaluating their coverage strategies as these drugs become a primary driver of rising pharmacy expenses.
由於每位病患的每月成本通常超過 1,000 美元，許多雇主正在重新評估其承保策略，因為這些藥物已成為藥房支出增加的主要驅動因素。
Currently, while over 90% of companies cover these drugs for Type 2 diabetes, only a minority provide coverage specifically for obesity.
目前，雖然超過 90% 的公司將這些藥物納入第二型糖尿病的承保範圍，但僅有少數公司專門提供肥胖症的承保。
The trend is shifting: in the past year, the number of employers covering GLP-1s for weight loss has dropped as companies struggle with uncertainty regarding long-term financial returns.
趨勢正在轉變：在過去一年中，由於公司在面對長期財務回報的不確定性時感到困難，提供 GLP-1 減重承保的雇主數量有所下降。
This creates a difficult balance for HR leaders, who must navigate intense employee demand for access against the need for financial sustainability.
這為人力資源主管帶來了艱難的平衡挑戰，他們必須在員工對藥物獲取的高需求與財務永續性的需求之間進行權衡。
While dropping coverage may offer short-term relief, some experts warn it could be a 'penny-wise but pound-foolish' approach that impacts long-term employee productivity and health outcomes.
雖然停止承保可能會提供短期緩解，但一些專家警告說，這可能是一種「因小失大」的做法，進而影響長期的員工生產力和健康成果。
